

The syndrome of Cardiogenic Insulin Resistance**Abstract**

Hyperglycemia in patients admitted in ICU with acute myocardial infarction is a common phenomena observed. This unique situation of insulin resistance does not spare diabetics or non diabetics. It is in addition to the inherent insulin resistance that is a part of DM2. It is brought about by various cytokines released from damaged heart muscle. This cardiogenic insulin resistance has cardiac as well as systemic counterparts. The grave and independent risk role in post MI complications, of the cardiac insulin resistance are highlighted. The concerted action of cardiologist and endocrinologist while in hospital is called for, so as to cover the gray areas between the two specialities, which otherwise falls into no man's island! The systemic insulin resistance, once it is back in home setting, would test the patience of the physician, as usual doses of insulin, just do not work! The article aims at creating awareness regarding concerted effects of all concerned to deliver holistic treatment to the patients.

Key Words :-

Cardiac insulin resistance, Post MI insulin resistance, Stent restenosis.

Cardiogenic insulin resistance (IR), manifesting

as hyperglycemia, is a well recognised entity in pts admitted with acute myocardial infarction (MI) in ICU, diabetic or non diabetic. IR, in the setting of acute MI has ominous prognosis.[1] This might sometimes be missed as un-controlled or undetected DM2. Cardiogenic IR is additional to, IR that is inherent to DM2. The result is that insulin doses that controlled DM2 before, fail to respond in the setting of cardiogenic IR. This cardiogenic IR is true even in cases of nondiabetic patients.[2] The Cardiogenic IR is either Cardiac, with or without systemic IR. Cardiac IR is widely discussed in the literature because of its grave consequences..- like high incidence failure (HF) [3,4], incomplete myocardial perfusion and CMF impairment. [5] Size of infarct is believed to be bigger. impairment of myocardial and microvasculature injury after STEMI injury. [7,8]

The prognostic relevance of hyperinsulinemia in STEMI patients[9] [10] and its relationship with coronary flow[11] are less well acknowledged.

IR was related to ischemic myocardial injury after elective PCI.

Cardiac remodeling, stent restenosis [12] are more common with Cardiac IR. Tachyarrhythmias were reported more [13] compared to controls.

Data connecting metabolic syndrome to the final infarct size are less clear.[14] However, evidences support direct proatherogenic effects of IR[15] as well as its direct adverse effects on myocardial contractility.

IR was related to ischemic myocardial injury after elective PCI[16] and in DKA with acute MI. [17]

The cardiologist can not ignore, the extra risk to patient because of the cardiac IR, in addition to the seriously compromised haemodynamic state of the heart. But the scourge of super speciality is

that DM2 is seen as not the concern of a cardiologist, but is the concern of an endocrinologist or a physician. Though DM, by virtue of Cardiac IR has many complications having bearing on cardiology, the cardiologist passes the buck to the endocrinologist. The latter's aim is solely to control hyperglycaemia and its complications. Thus, the monitoring, follow up and management, of issues arising out of Cardiac IR are likely to fall in no man's island. Can this be holistic treatment? Hence every case of cardiac IR should open up communication between the cardiologist and endocrinologist/ physician who are in charge of the DM2 aspect.

Lastly though stress hormones are implicated in the blunted action of insulin, in the early setting, the real culprit found to cause the damage to heart is the cytokines, TNF alpha, especially in cardiac IR.(18.).

Even TNF alpha inhibitors, like etanercept were effectively used in experimental animals in protecting against the deleterious effects of Cardiac IR on heart.

Of special interest is the systemic IR following an MI.

This persists for a week or two, even after the patient is discharged from ICU. Now the pt is in care of a family physician. He has little information or knowledge of persistent IR for some time even after an MI. It is certain to baffle him as to why the expected doses of insulin or doses that used to keep pts BS under control, just do not work any longer!. This leads naturally to additions and deletions of various anti diabetic armamentaria at his disposal. The result is a bigger mess! So there is a need to take into confidence, the family physician also, regarding issues concerning the cardiogenic IR. Inflammatory cytokines like, IL-6, CRP and plasminogen activation inhibitor factor 1 etc. have been implicated in the pathogenesis of cardiogenic systemic IR. Nondiabetic patients with AMI can

The best way to cope up with systemic IR due to MI, is to buy time till the blocking effects of the cytokines wears off when the regular previous doses of insulin become effective.

The purpose of this article is to create awareness of cardiogenic IR, as to its role in damage to ischemic heart and management problems of DM2 due to systemic IR.

Cardiogenic insulin resistance (IR), manifesting

as hyperglycaemia, is a well recognised entity in pts admitted with an MI in ICU, diabetic or non diabetic. IR in the setting of an MI has ominous prognosis.[1] This might sometimes be missed as un-controlled or undetected DM2. Cardiogenic IR is additional to it, IR that is inherent to DM2. The result is that insulin doses that controlled DM2 before, fail to respond in the setting of cardiogenic IR. This cardiogenic IR is true even in cases of nondiabetic pts.[2] The Cardiogenic IR is either Cardiac, with or without systemic IR.

Cardiac IR is widely discussed in literature because of its grave consequences..- like high incidence of HF[3,4], incomplete myocardial perfusion and CMF impairment. [5] Size of infarct is believed to be bigger. impairment of myocardial and microvasculature injury after STEMI injury. [7,8]

The prognostic relevance of hyperinsulinemia in STEMI patients[9] [10] and its relationship with coronary flow[11] are less well acknowledged.

IR was related to ischemic myocardial injury after elective PCI.

Cardiac remodeling, stent restenosis [12] are more common with Cardiac IR. Tachyarrhythmias were reported more [13] compared to controls.

Data connecting metabolic syndrome to the final infarct size are less clear.[14] However, evidences support direct proatherogenic effects of IR[15] as well as its direct adverse effects on myocardial contractility.

IR was related to ischemic myocardial injury after elective PCI[16] and in DKA with an MI. [17]

The cardiologist can not ignore, the extra risk to patient because of the cardiac IR, in addition to

the seriously compromised haemodynamic state of the heart. But the scourge of super speciality is that DM2 is seen as not the concern of a cardiologist, but is the concern of an endocrinologist or a physician. Though DM, by virtue of Cardiac IR has many complications having bearing on cardiology, the cardiologist passes the buck to the endocrinologist. The later aim is solely to control hyperglycaemia and its complications. Thus, the monitoring, follow-up and management, of issues arising out of Cardiac IR are likely to fall in no man's island. Can this be holistic treatment? Hence every case of cardiac IR should open communication between the cardiologist and endocrinologist/physician who are in charge to the DM2 aspect.

Lastly though stress hormones are implicated in the blunted action of insulin, in the early setting, the real culprit found to cause the damage to heart is the cytokine, TNF alpha, especially in cardiac IR.(18.).

Even TNF alpha inhibitors, like etanercept were effectively used in experimental animals in protecting against the deleterious effects of Cardiac IR on heart.

Of special interest is the systemic IR following an MI.

This persists for a week or so even after the pt is discharged from ICU. Now the pt is in care of a family physician. He has little information or knowledge of persistent IR for some time even after an MI. It is certain to baffle him as to why the expected doses of insulin or doses that used to keep pts BS under control, just do not work any longer!. This leads naturally to additions and deletions of various anti diabetic armamentaria at his disposal. The result is a bigger mess! So there is a need to take into confidence, the family physician also, regarding issues concerning the cardiogenic IR. Inflammatory cytokines like, IL-6, CRP and plasminogen activation inhibitor factor 1 etc. have been implicated in the pathogenesis of cardiogenic systemic IR. Nondiabetic patients with AMI can

The best way to cope up with systemic IR due to MI, is to buy time till the blocking effects of the cytokines wears off when the regular previous doses of insulin become effective.

The purpose of this article is to create awareness of cardiogenic IR, as to its role in damage to ischemic heart and management problems of DM2 due to systemic IR.

References:

- 1) Ingelsson E., Sundstrom J., Arnlov J., Zethelius B. & Lind L. Insulin resistance and risk of congestive heart failure. JAMA 294, 334–341 (2005). [PubMed]
- 2) Jeschke M. G., Klein D., Bolder U. & Einspanier R. Insulin attenuates the systemic inflammatory response in endotoxemic rats. Endocrinology 145, 4084–4093 (2004). [PubMed]
- 3) Ingelsson E., Sundstrom J., Arnlov J., Zethelius B. & Lind L. Insulin resistance and risk of congestive heart failure. JAMA 294, 334–341 (2005). [PubMed]
- 4) Swan J. W. et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol 30, 527–532 (1997). [PubMed]
- 5) Cohen-Solal A., Beauvais F. & Logeart D. Heart failure and diabetes mellitus: epidemiology and management of an alarming association. J Card Fail 14, 615–625 (2008). [PubMed]
- 6) Botker H. E., Moller N., Schmitz O., Bagger J. P. & Nielsen T. T. Myocardial insulin resistance in patients with syndrome X. J Clin Invest 100, 1919–1927 (1997). [PMC free article] [PubMed]
- 7) Nikolaidis L. A. et al. The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy. Cardiovasc Res 61, 297–306
- 8) treatment normalizes mitochondrial energetics and myocardial insulin sensitivity independently

- of changes in systemic metabolic homeostasis in a mouse model of the metabolic syndrome. *J Mol Cell Cardiol* 85, 104–116 (2015). [PMC free article][PubMed].
- 9) García RG, Rincón MY, Arenas WD, Silva SY, Reyes LM, Ruiz SL, Ramirez F, Camacho PA, Luengas C: injury via reducing oxidative/nitrative stress. *Am J Physiol Endocrinol Metab* 298, E871–E880 (2010). [PubMed]
- 10) Kragelund C, Snorgaard O, Køber L, Bengtsson B, Ottesen M, Højberg S, Olesen C, Kjaergaard JJ, Carlsen J, Torp-Petersen C, TRACE Study Group: Hyperinsulinaemia is associated with increased long-term mortality following acute myocardial infarction in non-diabetic patients. *Eur Heart J*. 2004, 25 (21): 1891-1897. 10.1016/j.ehj.2004.07.033.View ArticlePubMedGoogle Scholar
- 11)Panza-Nduli J, Coulic V, Willems D, Devriendt J, Gottignies P, Staroukine M, De Bels D: Influence of blood insulin measurement in acute coronary syndrome. *Crit Pathw Cardiol*. 2011, 10 (4): 185-188. 10.1097/HPC
- 12) Nishio KI, Shigimitsu M, Kushuyama T, Kawamura et al : insulin resistance in nondiabetic patients with acute myocardial infarction.*Cardiovasc Revasc Med*.2006 april- june;, 7 (2).54-60.
- 13) Z, Ozer N, Uyarel H, Akgul O, Gul M, Cetin M, Kasikcioglu H, Cam N: Metabolic syndrome is a predictor for an ECG sign of no-reflow after primary PCI in patients with acute ST-elevation myocardial infarction. *Nutr Metab Cardiovasc Dis*. 2008, 18 (6): 441-447. 10.1016/j.numecd.2007.02.015.View ArticlePubMedGoogle Scholar
- 14.)Bøhmer E, Seljeflot I, Arnesen H, Hoffmann P, Abdelnoor M, Halvorsen S: The association between metabolic syndrome and infarct size in patients with acute myocardial infarction. *Scand J Clin Lab Invest*. 2010, 70 (4): 287-293. 10.3109/00365513.2010.481819.View ArticlePubMed
- 15) Karrowni W, Li Y, Jones PG, Cresci S, Abdallah MS Lanfear DE, Maddox TM, McGuire DK, Spertus JA, Horwitz PA: Insulin resistance is associated with significant clinical atherosclerosis in nondiabetic Case Reports in *Endocrinology* Volume 2013 (2013), Article ID 520904, 7
- 16) Uetani T, Amano T, Harada K, Kitagawa K, Kunimura A, Shimbo Y, Harada K, Yoshida T, Kato B, Kato M, Marui N, Nanki M, Hotta N, Ishii H, Matsubara T, Murohara T: Impact of insulin resistance on post-procedural myocardial injury and clinical outcomes in patients who underwent elective coronary interventions with drug-eluting stents. *JACC Cardiovasc Interv*. 2012, 5 (11): 1159-1167. 10.1016/j.jcin.2012.07.008
- 17) H. Oo,¹ Jocelyne G. Karam,^{1,2} and Christine A. Resta. Extreme Insulin Resistance in a Patient with Diabetes Ketoacidosis and Acute Myocardial Infarction. *Case Reports in Endocrinology* Volume 2013 (2013), Article ID 520904, 7 17).
- 18) Irwin M. W. et al. Tissue expression and immunolocalization of tumor necrosis factor-alpha in postinfarction dysfunctional myocardium. *Circulation* 99, 1492–1498 (1999). [PubMed]